Axsome Therapeutics Inc. (AXSM) NASDAQ
$31.13 -2.45 (-7.30%)
Market Cap: $1.31B
As of 05/18/22 04:00 PM EDT. Market closed.
Axsome Therapeutics Inc. (AXSM) NASDAQ
$31.13 -2.45 (-7.30%)
Market Cap: $1.31B
As of 05/18/22 04:00 PM EDT. Market closed.
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome's core CNS product candidate portfolio includes five ... read more
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome's core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA. read less
Open in:
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Coleman Mark | Director | Mar 15, 2022 | Option Exercise | $1.30 | 3,496 | 4,545 | 7,596 | Mar 17, 2022, 07:05 AM |
| JEFFS ROGER | Director | Nov 19, 2021 | Buy | $37.30 | 3,950 | 147,350 | 120,756 | Nov 23, 2021, 07:30 AM |
| Pizzie Nick | CHIEF FINANCIAL OFFICER | Nov 18, 2021 | Buy | $35.50 | 527 | 18,709 | 41,789 | Nov 22, 2021, 07:31 AM |
| Pizzie Nick | CHIEF FINANCIAL OFFICER | Nov 18, 2021 | Buy | $34.97 | 428 | 14,968 | 201 | Nov 22, 2021, 07:31 AM |
| Coleman Mark | Director | Nov 18, 2021 | Buy | $35.09 | 1,430 | 50,181 | 422,428 | Nov 22, 2021, 07:30 AM |
| Saad Mark E | Director | Nov 17, 2021 | Buy | $34.42 | 300 | 10,325 | 100 | Nov 19, 2021, 07:30 AM |
| Saad Mark E | Director | Nov 17, 2021 | Buy | $34.53 | 3,000 | 103,597 | 10,002 | Nov 19, 2021, 07:30 AM |
| Coleman Mark | Director | May 12, 2021 | Buy | $58.15 | 500 | 29,075 | 420,998 | May 13, 2021, 07:05 AM |
| Coleman Mark | Director | Jun 29, 2020 | Buy | $78.50 | 650 | 51,025 | 403,698 | Jun 30, 2020, 08:20 AM |
| Pizzie Nick | Chief Financial Officer | Jun 29, 2020 | Buy | $76.64 | 777 | 59,549 | 41,217 | Jun 30, 2020, 08:19 AM |
| JEFFS ROGER | Director | Jan 10, 2020 | Option Exercise | $10.46 | 60,186 | 629,756 | 116,806 | Jan 14, 2020, 04:08 PM |
| Pizzie Nick | Chief Financial Officer | Sep 26, 2019 | Buy | $24.80 | 2,180 | 54,064 | 40,440 | Sep 30, 2019, 07:16 AM |
| JEFFS ROGER | Director | Jul 03, 2019 | Option Exercise | $3.04 | 56,620 | 172,178 | 56,620 | Jul 05, 2019, 07:00 AM |
| Coleman Mark | Director | Jun 26, 2019 | Buy | $23.10 | 15,800 | 364,980 | 668,848 | Jun 27, 2019, 07:18 AM |
| Coleman Mark | Director | Jun 25, 2019 | Buy | $23.25 | 400 | 9,300 | 653,048 | Jun 27, 2019, 07:18 AM |
| Pizzie Nick | Chief Financial Officer | Jun 11, 2019 | Buy | $20.80 | 1,920 | 39,936 | 1,920 | Jun 12, 2019, 07:00 AM |
| Saad Mark E | Director | May 23, 2019 | Buy | $22.33 | 3,500 | 78,155 | 7,002 | May 24, 2019, 07:19 AM |
| Coleman Mark | Director | May 13, 2019 | Buy | $21.44 | 4,650 | 99,696 | 652,648 | May 15, 2019, 07:21 AM |
| Pizzie Nick | Chief Financial Officer | Mar 19, 2019 | Buy | $12.69 | 60 | 761 | 60 | Mar 21, 2019, 07:05 AM |
| Pizzie Nick | Chief Financial Officer | Mar 19, 2019 | Buy | $12.58 | 5,340 | 67,177 | 36,340 | Mar 21, 2019, 07:05 AM |
| Coleman Mark | Director | Mar 19, 2019 | Buy | $12.18 | 5,100 | 62,118 | 5,100 | Mar 21, 2019, 07:05 AM |
| Pizzie Nick | Chief Financial Officer | Jun 19, 2018 | Buy | $3.10 | 31,000 | 96,080 | 31,000 | Jun 20, 2018, 05:00 PM |
| JEFFS ROGER | Director | Mar 29, 2017 | Option Exercise | $4.73 | 42,538 | 201,163 | 46,912 | Mar 30, 2017, 04:31 PM |
| Kaye Randall | Chief Medical Officer | Dec 23, 2015 | Buy | $9.03 | 1,000 | 9,026 | 6,022 | Dec 24, 2015, 01:02 PM |
| Ames Constance | Vice President, Finance | Nov 24, 2015 | Option Exercise | $5.94 | 4,358 | 25,887 | 4,358 | Nov 24, 2015, 04:26 PM |
| Kaye Randall | Chief Medical Officer | Nov 24, 2015 | Option Exercise | $5.40 | 5,022 | 27,119 | 5,022 | Nov 24, 2015, 04:26 PM |
| Coleman Mark | Director | Nov 24, 2015 | Option Exercise | $5.71 | 564,948 | 3,224,166 | 647,998 | Nov 24, 2015, 04:25 PM |
| JEFFS ROGER | Director | Nov 24, 2015 | Option Exercise | $5.94 | 4,374 | 25,982 | 4,374 | Nov 24, 2015, 04:25 PM |
| Saad Mark E | Director | Nov 24, 2015 | Option Exercise | $5.94 | 3,502 | 20,802 | 3,502 | Nov 24, 2015, 04:24 PM |
| TABUTEAU HERRIOT | Chief Executive Officer | Nov 24, 2015 | Option Exercise | $5.94 | 7,229 | 42,940 | 7,229 | Nov 24, 2015, 04:24 PM |
| Owner | Relationship | Date | Value($) |
| Coleman Mark | Director | 03/15/2022 | 4,545 |
| JEFFS ROGER | Director | 11/19/2021 | 147,350 |
| Pizzie Nick | CHIEF FINANCIAL OFFICER | 11/18/2021 | 18,709 |
| Pizzie Nick | CHIEF FINANCIAL OFFICER | 11/18/2021 | 14,968 |
| Coleman Mark | Director | 11/18/2021 | 50,181 |
| Saad Mark E | Director | 11/17/2021 | 10,325 |
| Saad Mark E | Director | 11/17/2021 | 103,597 |
| Coleman Mark | Director | 05/12/2021 | 29,075 |
| Coleman Mark | Director | 06/29/2020 | 51,025 |
| Pizzie Nick | Chief Financial Officer | 06/29/2020 | 59,549 |
| JEFFS ROGER | Director | 01/10/2020 | 629,756 |
| Pizzie Nick | Chief Financial Officer | 09/26/2019 | 54,064 |
| JEFFS ROGER | Director | 07/03/2019 | 172,178 |
| Coleman Mark | Director | 06/26/2019 | 364,980 |
| Coleman Mark | Director | 06/25/2019 | 9,300 |
| Pizzie Nick | Chief Financial Officer | 06/11/2019 | 39,936 |
| Saad Mark E | Director | 05/23/2019 | 78,155 |
| Coleman Mark | Director | 05/13/2019 | 99,696 |
| Pizzie Nick | Chief Financial Officer | 03/19/2019 | 761 |
| Pizzie Nick | Chief Financial Officer | 03/19/2019 | 67,177 |
| Coleman Mark | Director | 03/19/2019 | 62,118 |
| Pizzie Nick | Chief Financial Officer | 06/19/2018 | 96,080 |
| JEFFS ROGER | Director | 03/29/2017 | 201,163 |
| Kaye Randall | Chief Medical Officer | 12/23/2015 | 9,026 |
| Ames Constance | Vice President, Finance | 11/24/2015 | 25,887 |
| Kaye Randall | Chief Medical Officer | 11/24/2015 | 27,119 |
| Coleman Mark | Director | 11/24/2015 | 3,224,166 |
| JEFFS ROGER | Director | 11/24/2015 | 25,982 |
| Saad Mark E | Director | 11/24/2015 | 20,802 |
| TABUTEAU HERRIOT | Chief Executive Officer | 11/24/2015 | 42,940 |
Period of Report: 03/31/2022
10-K/10-Q Filings: View